Combining Simple Blood Tests Might Accelerate Diagnosis of Myeloma
The combination of two blood tests routinely ordered by general practitioners could speed the diagnosis of myeloma, according to a new study. The research,…
News
Revlimid-based Therapies are Best Maintenance Option for Newly-diagnosed Multiple Myeloma Patients, Analysis Finds
Maintenance treatments containing the immunomodulatory therapy Revlimid (lenalidomide) are the best option for patients with multiple myeloma, according to a recent meta-analysis. The study, “…
Amgen Seeks Expanded Approval of Kyprolis to Once-weekly Regimen for Relapsed Myeloma
Amgen is seeking to expand the approval of its proteasome inhibitor Kyprolis (carfilzomib) in the U.S. to include once-weekly dosing combined with dexamethasone for…
FDA Grants Priority Review to Empliciti Combo Therapy for Relapsed or Refractory Myeloma
The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) combined with Pomalyst (pomalidomide) and…
BL-8040 Speeds Collection of Stem Cells for Transplant in Myeloma Patients, Phase 3 Data Suggest
Adding BioLineRx‘s BL-8040 to standard treatment greatly improves the mobilization of blood stem cells to be collected for stem cell transplants in patients…
Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma
SRF231, an experimental anti-CD47 immunotherapy candidate developed by Surface Oncology, was granted orphan drug status by the U.S. Food and Drug Administration for…
Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma
The U.S. Food and Drug Administration has granted orphan drug status to SRF231 to treat multiple myeloma, according to Surface Oncology, which is developing…
CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients
Expanded use of Darzalex (daratumumab) in combination with standard therapy for treating adult patients with newly-diagnosed multiple myeloma, and who are not candidates for stem cell…
Machine-learning Algorithm Predicts Responses to Myeloma Treatments
Inserting data from genetically similar patients into a machine-learning algorithm may help predict which multiple myeloma patients will benefit from Velcade (bortezomib) or Revlimid (lenalidomide)…
Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests
Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because they can spot cases that…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML